Drug Search Results
More Filters [+]

Lorvotuzumab mertansine

Alternative Names: lorvotuzumab mertansine, bb-10901, imgn901
Latest Update: 2023-09-13
Latest Update Note: News Article

Product Description

Mechanisms of Action: CD56 Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lorvotuzumab mertansine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Small Cell Lung Cancer|Neurofibrosarcoma|Leukemia|Neuroblastoma|Pulmonary Blastoma|Synovial Sarcoma|Wilms Tumor|Rhabdomyosarcoma

Phase 1: Ovarian Cancer|Carcinoma, Merkel Cell|Small Cell Lung Cancer|Multiple Myeloma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ADVL1522

P2

Completed

Synovial Sarcoma|Pulmonary Blastoma|Wilms Tumor|Neurofibrosarcoma|Rhabdomyosarcoma|Neuroblastoma

2017-06-30

NCI-2015-00683

P2

Completed

Leukemia

2017-06-06

2010-022950-17

P2

Completed

Small Cell Lung Cancer

2015-05-12

Immunogen 0007

P2

Terminated

Small Cell Lung Cancer

2015-05-01

Recent News Events